Pulmonary vasodilators: beyond the bounds of pulmonary arterial hypertension therapy in COVID-19
Pulmonary vasodilators: beyond the bounds of pulmonary arterial hypertension therapy in COVID-19
About this item
Full title
Author / Creator
Publisher
London, England: SAGE Publications
Journal title
Language
English
Formats
Publication information
Publisher
London, England: SAGE Publications
Subjects
More information
Scope and Contents
Contents
Pulmonary arterial hypertension (PAH) and novel coronavirus (SARS-CoV-2) disease COVID-19 are characterized by extensive endothelial dysfunction and inflammation leading to vascular remodeling and severe microthrombi and microvascular obliterative disease. It is hypothesized that those patients with underlying lung disease, like PAH, represent a hi...
Alternative Titles
Full title
Pulmonary vasodilators: beyond the bounds of pulmonary arterial hypertension therapy in COVID-19
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_9dcb7a53efd44a27bc4a473f1b2e6007
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_9dcb7a53efd44a27bc4a473f1b2e6007
Other Identifiers
ISSN
2045-8940,2045-8932
E-ISSN
2045-8940
DOI
10.1177/2045894020970369
